CEO Marc Beer built and sold ViaCell to PerkinElmer, and prior to that he was a VP at Genzyme. He knows the game. If this drug gets FDA approval on December 29, I doubt that AEGR stays independent for long. High-buck drugs for rare diseases are in high demand, and AEGR's proven pipeline would make it a truly hot prospect.
. . . Question is -- at what premium? BMY bought Medarex to get full control of Yervoy for melanoma. They paid $2.2 billion. Based on that alone, I wouldn't think $1.6 billion would be out of the question. And that would put AEGR's share price at roughly $70 . . .